Date

Time

Venue

Discovery in scientific domains has always been attributed to human genius and creativity. Recent advancements in AI is making it possible to design interactive and intelligent systems that could accelerate and augment human creativity by taking larger responsibility for different stages of scientific discovery process.

In this talk, I will discuss this area in details, explore the current state-of-the-art and its challenges, focus on the AI approaches from Deep Generative Models to Active and Reinforcement Learning that can be used for generating novel scientific hypothesis. I will also draw real-life examples from our current attempts at using these methods in the field of Drug Discovery.

Bio: Amir is director of Applied AI at Benevolent AI. BenevolentAI’s initial scientific focus has been in human health, specifically rare disease groups in often overlooked areas. In human health, BenevolentAI has harnessed its technology to make major breakthroughs and accelerate drug development.. The Company has entered into significant license agreements with some of the world’s largest pharmaceutical companies and is beginning its first Phase IIb clinical study in 2017.

In 2016, total expenditure on prescription drugs in the US was estimated at $450 billion. During this year, almost half of the US population took at least one prescription medicine every month. It is essential that we find ways to streamline this process, removing inefficencies and unnecessary costs, while bringing efficacious prescription drugs to the population as soon as possible. We believe that Artificial Intelligence offers the best solutions to solve these issues.

The 5th annual Advanced Pharma Analytics Europe Summit 2018 is dedicated to bringing together Data Science and Advanced Analytics leaders to address the biggest challenges and opportunities in this space.

Join Ian Churcher, VP of Drug Discovery at BenevolentBio as he discusses Targeted Protein Degradation, one of the most exciting and fast growing areas of drug discovery. Ian will give an introduction to the area and highlight how AI approaches can be used to accelerate progress.